Country: Canada
Language: English
Source: Health Canada
ONDANSETRON
AURO PHARMA INC
A04AA01
ONDANSETRON
8MG
TABLET (ORALLY DISINTEGRATING)
ONDANSETRON 8MG
ORAL
15G/50G
Prescription
5-HT3 RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0131120001; AHFS:
APPROVED
2021-01-20
Page 1 of 35 _PRODUCT MONOGRAPH _ _AURO-ONDANSETRON ODT_ _ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR AURO-ONDANSETRON ODT Ondansetron Orally Disintegrating Tablets Orally Disintegrating Tablets, 4 mg and 8 mg, Oral House Standard Antiemetic 5-HT 3 receptor antagonist ATC code A04AA01 Auro Pharma Inc. 3700 Steeles Avenue West, Suite # 402 Woodbridge, Ontario, L4L 8K8, Canada. Date of Initial Authorization: January 20, 2021 Date of Revision: September 08, 2022 Submission Control Number: 261680 Page 2 of 35 _PRODUCT MONOGRAPH _ _AURO-ONDANSETRON ODT_ _ _ RECENT MAJOR LABEL CHANGES 1 INDICATIONS, Adults (18-64 years of age) 09/2022 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dose Adjustment 09/2022 7 WARNINGS AND PRECAUTIONS, Cardiovascular, Myocardial Ischemia and Coronary Artery Spasm 09/2022 7 WARNINGS AND PRECAUTIONS, Special Populations, 7.1.1 Pregnant Women 01/2021 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .......................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS .................................................................................................................... 4 1.1 Pediatrics (<18 years of age) ....................................................................................... 4 1.2 Geriatrics (≥65 years of age) ....................................................................................... 4 2 CONTRAINDICATIONS ....................................................................................................... 4 4 DOSAGE AND ADMINISTRATION ....................................................................................... 5 4.1 Dosing Considerations ................................................................................................ 5 4.2 Recommended Dose and Dosage Adjustment Read the complete document